Idenix Pharmaceuticals (IDIX)

[go seek]

Tyzeka prescriptions as of 4/27
>> also see
http://www.siliconinvestor.com/readmsg.aspx?msgid=23524864

4/27: 80 NRx, 161 TRx;
4/20: 76 NRx, 146 TRx;
4/13: 61 NRx, 135 TRx; 2.9% new, 1.9% total
04/6: 82 NRx, 137 TRx;
3/30: 87 NRx, 142 TRx; 3.9% new, 2.0% total
3/23: 55 NRx.., 90 TRx; 2.7% new, 1.3% total
2/23: 59 NRx.., 92 TRx; 3.1% new, 1.4% total
02/9: 55 NRx.., 83 TRx; 2.6% new, 1.2% total
1/26: 41 NRx.., 60 TRx; 2.0% new, 0.9% total

The "new" figure refers to Tyzeka’s market share in the given week among new prescriptions for all HBV drugs.

The "total" figure refers to Tyzeka’s market share in the given week among total prescriptions—new and refills—for all HBV drugs.

For a recently-launched drug such as Tyzeka, the market share of new prescriptions is a more useful gauge than the market share of total prescriptions.